| Code | CSB-RA023603MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to paridiprubart, targeting Toll-like receptor 4 (TLR4), a critical pattern recognition receptor in the innate immune system. TLR4 serves as the primary sensor for lipopolysaccharide (LPS) from Gram-negative bacteria, initiating inflammatory signaling cascades through MyD88-dependent and TRIF-dependent pathways. Upon activation, TLR4 triggers the production of pro-inflammatory cytokines and type I interferons, playing essential roles in host defense against pathogens. Dysregulated TLR4 signaling is implicated in numerous pathological conditions, including sepsis, inflammatory bowel disease, atherosclerosis, rheumatoid arthritis, and various autoimmune disorders.
Paridiprubart represents a therapeutic antibody designed to modulate TLR4 activity and dampen excessive inflammatory responses. This biosimilar provides researchers with a valuable tool for investigating TLR4-mediated immune mechanisms, studying inflammatory disease pathogenesis, and exploring potential therapeutic interventions in conditions characterized by aberrant innate immune activation. The antibody enables detailed examination of TLR4 biology across various experimental models and cellular systems.
There are currently no reviews for this product.